PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% of Pharmadrug Production GmbH (“Pharmadrug Production”), a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. PharmaDrug owns 100% Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms as natural based medicines.

La société se concentre sur la réutilisation de médicaments grâce à l'intelligence artificielle. La plate-forme d’intelligence artificielle de réutilisation des médicaments de la société combine des processus multicouches permettant d’intégrer des millions de points de données et d’effectuer un apprentissage automatique pour découvrir de nouvelles utilisations des médicaments.

PlantFuel Life Inc. est une société de sciences de la vie spécialisée dans la culture, la production et la vente de chanvre industriel.

Predictmedix AI Inc. is an artificial intelligence ("AI") company developing disruptive and cutting-edge tools for impairment testing and healthcare testing. The Issuer's proprietary technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. The Issuer is also developing cutting edge screening technologies for the healthcare industry.  Predictmedix is expanding its proprietary AI technology to screen for infectious diseases, and also to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.